FGF21 demonstrates direct cardioprotective effects and potential therapeutic prospects for improving myocardial energetics and function in obesity and T2DM through its pleiotropic actions (metabolic improvement, inflammation reduction, and fibrosis suppression), with related drugs currently in clinical development. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.